Zentalis Pharmaceuticals Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Zentalis Pharmaceuticals hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$3.08
Erwartete Dividendenrendite in 3 Jahren	0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Jun 13

Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit

May 09

Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling

Apr 12

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Feb 29

Zentalis: Leading WEE1 Developer After AstraZeneca's Exit

Feb 05

Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?

Jan 09

We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate

Oct 13

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Jun 30

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Mar 17

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Dec 01

Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer

Sep 27

Zentalis Pharmaceuticals has a new chief medical officer

Sep 19

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans

Aug 17

Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

May 02

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Jan 12

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Oct 14

Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Jul 02

Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?

Mar 08

Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth

Jan 20

Zentalis initiates multiple early-stage clinical trials for cancer

Jan 06

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von ZNTL in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von ZNTL gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Zentalis Pharmaceuticals Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von ZNTL im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (ZNTL)	n/a
Untere 25 % des Marktes (US)	1.6%
Markt Top 25 % (US)	4.8%
Branchendurchschnitt (Biotechs)	2.8%
Analystenprognose in 3 Jahren (ZNTL)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von ZNTL im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von ZNTL im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von ZNTL, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da ZNTL keine Ausschüttungen gemeldet hat.

Zentalis Pharmaceuticals Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Zentalis Pharmaceuticals Announces Appointment of Luke Walker, M.D., to Board of Directors

Now 24% overvalued

Zentalis Pharmaceuticals, Inc. to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting

Price target decreased by 8.9% to US$32.44

Consensus revenue estimates increase by 315%

Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit

Now 21% overvalued after recent price rise

Zentalis Pharmaceuticals, Inc., Annual General Meeting, Jun 21, 2024

Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling

Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating That Wee1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity with Kras(G12c) Inhibitors At Aacr Annual Meeting 2024

Zentalis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Zentalis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Zentalis: Leading WEE1 Developer After AstraZeneca's Exit

Co-Founder notifies of intention to sell stock

Zentalis Pharmaceuticals, Inc. Announces Executive Changes

Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?

Independent Chairman of the Board recently bought US$168k worth of stock

Zentalis Pharmaceuticals, Inc. Announces Executive Changes

Price target decreased by 21% to US$39.10

New minor risk - Share price stability

We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate

Chief Medical Officer notifies of intention to sell stock

Zentalis Pharmaceuticals, Inc. Appoints Kimberly Freeman as Chief Strategy Officer

We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth

Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) dropped from Russell Small Cap Comp Value Index

Zentalis Pharmaceuticals, Inc. Announces Potential for Azenosertib (Zn-C3) to Address Large Unmet Need Across an Array of Cancers

Price target increased by 11% to US$51.78

Co-Founder notifies of intention to sell stock

High number of new directors

Zentalis Announces Presentation of Positive Phase 1B Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy

Price target decreased by 12% to US$45.90

Zentalis Pharmaceuticals, Inc. Appoints Diana Hausman to the Board of Directors

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Zentalis Pharmaceuticals, Inc. Appoints Iris Roth as Chief Operating Officer

Co-Founder notifies of intention to sell stock

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Less than half of directors are independent

Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy

Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy

Zentalis Pharmaceuticals, Inc. Promotes Co-Founder Kevin Bunker to Chief Scientific Officer

Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer

Zentalis Pharmaceuticals, Inc. Appoints Carrie Brownstein as Chief Medical Officer

Co-Founder notifies of intention to sell stock

Zentalis Pharmaceuticals has a new chief medical officer

Zentalis Pharmaceuticals, Inc Appoints Dr. Jan Skvarka to Its Board of Directors

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$72.50

Chief Operating Officer notifies of intention to sell stock

Zentalis Pharmaceuticals, Inc. Announces Resignation of Alexis M. Pinto as Chief Legal Officer and Secretary of the Company, Effective July 5, 2022

Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President

Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President

Less than half of directors are independent

Zentalis Pharmaceuticals, Inc. Announces Management Changes

Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

Price target decreased to US$85.70

Zentalis Pharmaceuticals, Inc. Announces the Interim Data from the Ongoing Phase 1/2 Clinical Trial Evaluating Zn-c3 as a Monotherapy for the Treatment of Advanced Solid Tumors

Price target decreased to US$90.80

CFO & Treasurer notifies of intention to sell stock

Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-C3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR

Chief Operating Officer notifies of intention to sell stock

President notifies of intention to sell stock

Insider exercised options and sold US$1.3m worth of stock

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Chief Operating Officer recently sold US$781k worth of stock

Secretary & Director notifies of intention to sell stock

Price target increased to US$97.67

President notifies of intention to sell stock

Chief Legal Officer & Secretary exercised options and sold US$1.3m worth of stock

Price target increased to US$87.78

We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Zentalis Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 1/2 Study of ZN-C3 in Combination with Gemcitabine in Patients with Osteosarcoma